Immunotherapy of cytomegalovirus infection after stem-cell transplantation: A new option?

Lancet

Volumn 362, Issue 9393, 2003, Pages 1343-1344

  Einsele, Hermann ^a   Hamprecht, Klaus ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; CYTOMEGALOVIRUS ANTIBODY; FOSCARNET; GANCICLOVIR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIMICROBIAL THERAPY; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; GENOTYPE PHENOTYPE CORRELATION; HERPES; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION PREVENTION; INFECTION RISK; NEUTROPENIA; NOTE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SUPERINFECTION; T LYMPHOCYTE ACTIVATION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS STRAIN;

EID: 0242317393     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14673-9     Document Type: Note

References (14)

1. Boeckh M., Ljungman P. Cytomegalovirus infection after hemopoietic stem cell transplantation. Bowden R.A., Ljungman P., Paya C.V. Transplant infections. 2nd edn:2003;277-297 Lippincott Williams and Wilkins, Philadelphia.
2. Goodrich J.M., Bowden R.A., Fisher L., Keller C., Schoch G., Meyers J.D. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med. 18:1993;173-178.
3. Boeckh M., Gooley T.A., Myerson D., Cunningham T., Schoch G., Bowden R.A. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood. 88:1996;4063-4071.
4. Einsele H., Ehninger G., Hebart H., et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood. 86:1995;2815-2820.
5. Einsele H., Hebart H., Kauffmann-Schneider C., et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant. 25:2000;757-763.
6. Hakki M., Riddell S.R., Storek J., et al. Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation. Blood. 102:2003;3060-3067.
7. Limaye A.P. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin Infect Dis. 35:2002;866-872.
8. Gilbert C., Bestman-Smith J., Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Update. 5:2002;88-114.
9. Eckle T., Prix L., Jahn G., et al. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood. 96:2000;3286-3290.
10. Eckle T., Lang P., Prix L., et al. Rapid development of ganciclovir-resistant cytomegalovirus infection in children after allogeneic stem cell transplantation in the early phase of immune cell recovery. Bone Marrow Transplant. 30:2002;433-439.
11. Hamprecht K., Eckle T., Prix L., Faul C., Einsele H., Jahn G. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis. 187:2003;139-143.
12. Riddell S.R., Watanabe K.S., Goodrich J.M., Li C.R., Agha M.E., Greenberg P.D. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science. 257:1992;238-241.
13. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 333:1995;1038-1044.
14. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood. 99:2002;3916-3922.